Arizona-based Strive Compounding Pharmacy filed a federal antitrust lawsuit against Eli Lilly and Novo Nordisk in a Texas district court.[1][2][3] The suit alleges that these pharmaceutical companies are coordinating efforts to stifle competition in GLP-1RA drugs such as Ozempic and Mounjaro by blocking access to combination versions.[1][4] Strive accuses Lilly and Novo of defaming compounded GLP-1 drugs as dangerous, illegal, or adulterated, even though individual compounding is permitted by federal law under Section 503A.[2][3] Further, the companies are alleged to interfere with relationships with physicians, telehealth platforms, payment processors, and online communities, thereby discouraging the prescription of combination therapies.[2][4] The main point is the conclusion of exclusive agreements with telehealth providers, which prohibit cooperation with combinators and conditionally allow access to original medicines.[1][2][4] Strive is seeking an injunction to rescind these exclusive agreements, an injunction against defamation, and other remedies, including damages.[2][3] Both companies deny the allegations.[1]